EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical Translation of Fisetin for Age-Related Diseases: Current Evidence and Future Opportunities

Carolina Sandoval-Caballero iD, Zander Roemer iD, Catherine M Kotz iD, Michael A Puskarich iD, Vijayakumar Mavanji iD, Elizabeth L Schmidt iD, Shalamar D Sibley iD

Nutrients · 2026

DOI: 10.3390/nu18182999 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrients, 2026. Verfasst von Carolina Sandoval-Caballero und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, MN 55455, USA. Hauptthemen laut MEDLINE: Aging, Flavonoids, Translational Research, Biomedical, Anti-Inflammatory Agents. Die Arbeit nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: RRD VA, NIDDK NIH HHS, United States Department of Veterans Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fisetin, a naturally occurring flavonoid, has garnered interest as a potential intervention for age-related diseases due to its anti-inflammatory, antioxidant, and senolytic properties, as demonstrated primarily in preclinical studies. We conducted a structured search and evaluated human translational and clinical studies that utilize fisetin to improve clinical markers associated with age-related low-grade inflammatory diseases. Building on preclinical work and observational studies in humans consuming flavonoid-rich diets or supplements, we evaluated 34 registered clinical trials on ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) with a focus on aging/frailty, metabolic diseases, cancer, cardiovascular diseases, neuroimmune/neurodegenerative diseases, and other chronic age-related diseases. We provide the status of the 34 registered trials and a synthesis and discussion of the 4 completed trials with available results that included fisetin, identifying gaps and areas for future investigation. Overall, the completed trials indicate that clinical evidence for fisetin remains limited and heterogeneous. While some studies reported favorable changes in metabolic or inflammatory outcomes, others found no clear or significant clinical benefit. Interpretation is further limited by small sample sizes, multimodal interventions, and uncontrolled or exploratory designs, making it difficult to establish fisetin efficacy in humans. Early findings in animal models and in human cell lines suggest that fisetin has the potential to mitigate age-related diseases by targeting chronic inflammation and oxidative stress driven by increased senescent cell burden, but more clinical data are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AgingFlavonoidsTranslational Research, BiomedicalAnti-Inflammatory AgentsHumansFlavonolsAnimalsAntioxidantsNeurodegenerative DiseasesCardiovascular DiseasesNeoplasmsClinical Trials as TopicMetabolic Diseases

Stichwörter der Autor:innen

agingcancercardiovascular diseaseclinical trialsfisetinfrailtyinflammationneurodegenerationobesity

Substanzen

fisetinFlavonolsFlavonoidsAntioxidantsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, MN 55455, USA.
  • Geriatric Research, Education and Clinical Center (GRECC), Minneapolis VA Health Care Center, Minneapolis, MN 55417, USA.
  • Department of Emergency Medicine, University of Minnesota, Minneapolis, MN 55364, USA.
  • Department of Emergency Medicine, Hennepin Healthcare, Minneapolis, MN 55364, USA.
  • Research Service, Minneapolis VA Health Care System, Minneapolis, MN 55417, USA.
  • Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA.

ORCID-Profile: Carolina Sandoval-Caballero, Zander Roemer, Catherine M Kotz, Michael A Puskarich, Vijayakumar Mavanji, Elizabeth L Schmidt, Shalamar D Sibley

Förderung

  • RRD VA
  • NIDDK NIH HHS
  • United States Department of Veterans Affairs
  • U.S. Department of Veterans Affairs
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Sandoval-Caballero, C., Roemer, Z., Kotz, C. M., Puskarich, M. A., Mavanji, V., Schmidt, E. L., & Sibley, S. D. (2026). Clinical Translation of Fisetin for Age-Related Diseases: Current Evidence and Future Opportunities. Nutrients. https://doi.org/10.3390/nu18182999

Vancouver

Sandoval-Caballero C, Roemer Z, Kotz CM, Puskarich MA, Mavanji V, Schmidt EL, et al. Clinical Translation of Fisetin for Age-Related Diseases: Current Evidence and Future Opportunities. Nutrients. 2026. doi:10.3390/nu18182999

BibTeX
@article{SandovalCaballero2026,
  author = {Sandoval-Caballero, Carolina and Roemer, Zander and Kotz, Catherine M and Puskarich, Michael A and Mavanji, Vijayakumar and Schmidt, Elizabeth L and Sibley, Shalamar D},
  title = {Clinical Translation of Fisetin for Age-Related Diseases: Current Evidence and Future Opportunities},
  journal = {Nutrients},
  year = {2026},
  doi = {10.3390/nu18182999}
}
Kostenlos starten →